Barry Buckland Joins InDevR's Board of Directors

BOULDER, Colo., November 12, 2019 (Newswire.com) - ​​​​InDevR, Inc., a biotechnology company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, today announced that Dr. Barry Buckland is joining the company’s Board of Directors effective Jan. 1, 2019. Dr. Buckland has more than 30 years of real-world experience in addressing vaccine bioprocessing issues to the InDevR team as they scale up commercial efforts following a recent Series A investment.

“Barry is an amazing person and an outstanding bioprocess engineer - we feel very fortunate to have him join our team. The wealth of experience in vaccine development that Barry brings with him along with his global network within the vaccine industry will no doubt be tremendously helpful in our commercial expansion efforts for the VaxArray and Cypher One product lines,” stated InDevR’s CEO, Dr. Kathy Rowlen.

Dr. Buckland is currently the Executive Director of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Chair of the Board of Engineering Conferences International and the CEO of BiologicB. After obtaining a Ph.D. in Biochemical Engineering from University of College in London, Barry started his career at Abbott Laboratories. He joined Merck in 1980 and quickly moved up the ranks to Vice President of Bioprocess R&D. During his 29 years at Merck, he oversaw the successful process development of vaccines against human papilloma virus, shingles, hepatitis A, rotavirus and chickenpox resulting in licensure and successful commercialization. Since leaving Merck he was leader of the Process Development team at Protein Sciences resulting in the FDA approval of Flublok®; the first recombinant protein-based influenza vaccine. Barry has received numerous accolades for his professional accomplishments, including the Donald Medal from the UK Institute of Chemical Engineering, the Marvin Johnson Award for Biotechnology and election to membership within the prestigious US National Academy of Engineering.

Dr. Buckland commented: “I am excited to join InDevR and support their efforts to provide innovative new tools to help streamline bioprocess analysis. Many of the assays used to characterize vaccines are long overdue for modernization. InDevR is focused on rapid, accurate, and precise antigen quantification and identity test kits that can be applied throughout the manufacturing process. By replacing time-consuming biological tests and expensive animal testing, InDevR’s products will ultimately result in lowering vaccine manufacturing costs and reducing the time to market.”

About InDevR—InDevR is a biotechnology company poised to significantly impact vaccine process optimization and manufacturing with powerful new protein characterization tools. The VaxArray® platform offers rapid multiplexed protein quantification for bioprocess development, improvement and monitoring as well as identity and potency testing. The VaxArray Influenza product line includes off-the-shelf reagent kits for seasonal and pre-pandemic hemagglutinin, seasonal and pre-pandemic neuraminidase and nucleoprotein. The Cypher One system is an affordable automated reader for hemagglutination and hemagglutination inhibition assays. Both product lines offer unprecedented data integrity through digital records and 21CFR Part 11 ready software.

For more information please visit www.indevr.com.

Source: InDevR, Inc.